» Articles » PMID: 24713737

Comparison of the APTT with Alternative Tests for Monitoring Direct Thrombin Inhibitors in Patient Samples

Overview
Specialty Pathology
Date 2014 Apr 10
PMID 24713737
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: The activated partial thromboplastin time (aPTT) test has been used for years to monitor parenteral direct thrombin inhibitors (DTIs) and unfractionated heparin. Because the aPTT correlates poorly with unfractionated heparin levels, we hypothesized that the aPTT may not be the best test for monitoring parenteral DTIs.

Methods: Using 235 excess plasma specimens from 82 adult patients receiving treatment with DTIs (argatroban, bivalirudin, or dabigatran), we compared the aPTT with the ecarin chromogenic assay (ECA), the dilute thrombin time (dTT) test, and the prothrombinase-induced clotting time (PiCT) test.

Results: The aPTT correlated poorly with each of the other tests in both bivalirudin- and argatroban-containing samples (r(2) = 0.04-0.23). The ECA and dTT exhibited the best correlations (r(2) = 0.66-0.93). Intermediate correlations were seen when the results of the PiCT were plotted against the dTT or ECA (r(2) = 0.46-0.58). Nineteen specimens obtained from six patients receiving dabigatran showed a good correlation between the dTT and the ECA (r(2) = 0.92).

Conclusions: The aPTT does not correlate well with other tests that might be used to monitor parental DTI administration. Further studies are needed to evaluate the clinical usefulness of alternative tests and their correlation with clinical outcomes.

Citing Articles

Explainable machine learning models for early gastric cancer diagnosis.

Du H, Yang Q, Ge A, Zhao C, Ma Y, Wang S Sci Rep. 2024; 14(1):17457.

PMID: 39075116 PMC: 11286780. DOI: 10.1038/s41598-024-67892-z.


Anticoagulation Monitoring and Targets: The Pediatric Extracorporeal Membrane Oxygenation Anticoagulation CollaborativE Consensus Conference.

Ozment C, Alexander P, Chandler W, Emani S, Hyslop R, Monagle P Pediatr Crit Care Med. 2024; 25(7 Suppl 1):e14-e24.

PMID: 38959356 PMC: 11216399. DOI: 10.1097/PCC.0000000000003494.


Is it time to switch to bivalirudin for ECMO anticoagulation?.

Navaei A, Kostousov V, Teruya J Front Med (Lausanne). 2023; 10:1237601.

PMID: 37671395 PMC: 10476497. DOI: 10.3389/fmed.2023.1237601.


Assays to Monitor Bivalirudin.

Davidson S Methods Mol Biol. 2023; 2663:369-380.

PMID: 37204724 DOI: 10.1007/978-1-0716-3175-1_24.


Novel Monitoring and Dose Adjustment of Argatroban, a Direct Thrombin Inhibitor, to Maintain Therapeutic Anticoagulation in a Patient With Antiphospholipid Antibody Syndrome, Heparin-Induced Thrombocytopenia, and COVID-19 Pneumonia.

Ryan C, Newman K, Roberts R, Frydman G, Rosovsky R Crit Care Explor. 2023; 5(4):0903.

PMID: 37114202 PMC: 10129108. DOI: 10.1097/CCE.0000000000000903.